418 related articles for article (PubMed ID: 18045300)
1. Mycophenolate mofetil therapy for children with intractable nephrotic syndrome.
Okada M; Sugimoto K; Yagi K; Yanagida H; Tabata N; Takemura T
Pediatr Int; 2007 Dec; 49(6):933-7. PubMed ID: 18045300
[TBL] [Abstract][Full Text] [Related]
2. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome.
Gellermann J; Ehrich JH; Querfeld U
Nephrol Dial Transplant; 2012 May; 27(5):1970-8. PubMed ID: 21976740
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome.
Bagga A; Hari P; Moudgil A; Jordan SC
Am J Kidney Dis; 2003 Dec; 42(6):1114-20. PubMed ID: 14655181
[TBL] [Abstract][Full Text] [Related]
4. [Mycophenolate mofetil versus cyclosporine A in children with primary refractory nephrotic syndrome].
Geng HY; Ji LN; Chen CY; Tu J; Li HR; Bao R; Lin Y
Zhonghua Er Ke Za Zhi; 2018 Sep; 56(9):651-656. PubMed ID: 30180402
[No Abstract] [Full Text] [Related]
5. [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].
Kwinta-Rybicka J; Wilkosz K; Wierzchowska-Słowiacze EK; Ogarek I; Moczulska A; Stec Z; Pełkowska A; Sancewicz-Pach K; Pietrzyk JA
Przegl Lek; 2006; 63 Suppl 3():44-8. PubMed ID: 16898486
[TBL] [Abstract][Full Text] [Related]
6. Switch from cyclosporine A to mycophenolate mofetil in nephrotic children.
Ulinski T; Dubourg L; Saïd MH; Parchoux B; Ranchin B; Cochat P
Pediatr Nephrol; 2005 Apr; 20(4):482-5. PubMed ID: 15719253
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome.
Sinha A; Gupta A; Kalaivani M; Hari P; Dinda AK; Bagga A
Kidney Int; 2017 Jul; 92(1):248-257. PubMed ID: 28318625
[TBL] [Abstract][Full Text] [Related]
8. A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study.
Li X; Tian J; Wu J; He Q; Li H; Han F; Li Q; Chen Y; Ni Q; Chen J
Clin Ther; 2009 Apr; 31(4):741-50. PubMed ID: 19446147
[TBL] [Abstract][Full Text] [Related]
9. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome.
Wang J; Mao J; Chen J; Fu H; Shen H; Zhu X; Liu A; Shu Q; Du L
Nephrology (Carlton); 2016 Jan; 21(1):21-7. PubMed ID: 26697959
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome.
Mendizábal S; Zamora I; Berbel O; Sanahuja MJ; Fuentes J; Simon J
Pediatr Nephrol; 2005 Jul; 20(7):914-9. PubMed ID: 15891923
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil for sustained remission in nephrotic syndrome.
Querfeld U; Weber LT
Pediatr Nephrol; 2018 Dec; 33(12):2253-2265. PubMed ID: 29750317
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group.
Hogg RJ; Fitzgibbons L; Bruick J; Bunke M; Ault B; Baqi N; Trachtman H; Swinford R
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1173-8. PubMed ID: 17699344
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center.
Fujinaga S; Ohtomo Y; Hirano D; Nishizaki N; Someya T; Ohtsuka Y; Kaneko K; Shimizu T
Clin Nephrol; 2009 Oct; 72(4):268-73. PubMed ID: 19825332
[TBL] [Abstract][Full Text] [Related]
15. Three year outcome of childhood idiopathic nephrotic syndrome under a unified immunosuppressive protocol.
Hibino S; Uemura O; Nagai T; Yamakawa S; Iwata N; Ito H; Nakano M; Tanaka K
Pediatr Int; 2015; 57(1):85-91. PubMed ID: 25225083
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children.
Basu B; Babu BG; Mahapatra TK
Clin Exp Nephrol; 2017 Feb; 21(1):143-151. PubMed ID: 27108294
[TBL] [Abstract][Full Text] [Related]
17. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome.
Barletta GM; Smoyer WE; Bunchman TE; Flynn JT; Kershaw DB
Pediatr Nephrol; 2003 Aug; 18(8):833-7. PubMed ID: 12774223
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine.
Fujinaga S; Hirano D; Nishino T; Umeda C; Watanabe Y; Nakagawa M
Pediatr Nephrol; 2019 Nov; 34(11):2417-2421. PubMed ID: 31435725
[TBL] [Abstract][Full Text] [Related]
19. Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil.
Gellermann J; Querfeld U
Pediatr Nephrol; 2004 Jan; 19(1):101-4. PubMed ID: 14753204
[TBL] [Abstract][Full Text] [Related]
20. Immunosupressive therapy in children with steroid-resistant nephrotic syndrome: single center experience.
Echeverri CV; Valencia GA; Higuita LM; Gayubo AK; Ochoa CL; Rosas LF; Muñoz LC; Sierra J; Zuleta JJ; Ruiz JJ
J Bras Nefrol; 2013; 35(3):200-5. PubMed ID: 24100739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
